{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:48:42Z","timestamp":1791204522659,"version":"4.2.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T00:00:00Z","timestamp":1451347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0144746","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T18:55:25Z","timestamp":1451415325000},"page":"e0144746","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice"],"prefix":"10.1371","volume":"10","author":[{"given":"Val\u00e9rie","family":"Potard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Finkielsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FHDH ANRS CO4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,12,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/01.aids.0000162337.58557.3d","article-title":"Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice","volume":"19","author":"AN Phillips","year":"2005","journal-title":"AIDS"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/135965350300800510","article-title":"Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected individuals enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS088)","volume":"8","author":"M Vray","year":"2003","journal-title":"Antiviral Therapy"},{"key":"ref3","unstructured":"Panel on Clinical pratices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1 Infected Adults and Adolescents: Aidsinfo, Feb 12, 2013. Available: http:\/\/www.aidsinfo.nih.gov\/guidelines\/archive\/adult-and-adolescent-guidelines\/<\/ext-link>"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in individuals infected with HIV-1","volume":"11","author":"G F\u00e4tkenheuer","year":"2005","journal-title":"Nature Medicine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated individuals with R5 HIV-1 infection","volume":"359","author":"RM Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"ref6","article-title":"Maraviroc 150 mg daily plus lopinavir\/ritonavir, a nucleoside\/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studyStudy","author":"S Nozza","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/598965","article-title":"A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Individuals Infected with Non-R5 HIV-1","volume":"199","author":"M Saag","year":"2009","journal-title":"JID"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/QAI.0b013e31820a9ae4","article-title":"Durability and safety of a novel salvage therapy in R5-tropic HIV-infected individuals: maraviroc, raltegravir, etravirine","volume":"56","author":"S Nozza","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1310\/hct1106-351","article-title":"The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients","volume":"11","author":"TJ Wilkin","year":"2010","journal-title":"HIV Clin Trials"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1468-1293.2011.00953.x","article-title":"Efficacy of new antiretroviral drugs in treatment\u2010experienced HIV\u2010infected patients: a systematic review and meta\u2010analysis of recent randomized controlled trials","volume":"13","author":"M Pichenot","year":"2012","journal-title":"HIV medicine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/QAI.0b013e318273015f","article-title":"ANRS 145 MARIMUNO Study group. Maraviroc Intensification of Stable Antiviral Therapy in HIV-1\u2013Infected Patients With Poor Immune Restoration: MARIMUNO-ANRS 145 Study","volume":"61","author":"L Cuzin","year":"2012","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/infdis\/jis376","article-title":"A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256","volume":"206","author":"Timothy J Wilkin","year":"2012","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/QAI.0b013e318230372e","article-title":"Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ARTCC Cohort Study","volume":"58","author":"MJ Mugavero","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref14","first-page":"1","article-title":"Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4)","author":"M Mary-Krause","year":"2014","journal-title":"Int. J. Epidemiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1128\/AAC.00148-10","article-title":"Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study","author":"Patricia Recordon-Pinson","year":"2010","journal-title":"Antimicrobiol Agents and Chemotherapy"},{"issue":"RR-17","key":"ref16","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","article-title":"Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Individuals With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2","volume":"55","author":"WD Hardy","year":"2010","journal-title":"Acquir Immune Defic Syndr"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/aid.2012.0235","article-title":"Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Individuals in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments","volume":"30","author":"B Rossetti","year":"2014","journal-title":"Aids Research and Human Retroviruseses"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1128\/AAC.00753-11","article-title":"Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Individuals: Frequency of Subjects with Virological Response and Associated Factors","author":"E Ruiz-Mateos","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref20","article-title":"Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response","author":"C Soulie","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3851\/IMP1759","article-title":"Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients","volume":"16","author":"MJ Shapiro","year":"2011","journal-title":"Antiviral Therapy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection","volume":"359","author":"G F\u00e4tkenheuer","year":"2008","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/2047-783X-15-6-231","article-title":"Maraviroc in treatment-experienced individuals with HIV-1 infection\u2014Experience from routine clinical practice","volume":"15","author":"S Reuter","year":"2010","journal-title":"Eur J Med Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1097\/00002030-200410210-00007","article-title":"Immunologic and clinical responses to higly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV","volume":"18","author":"S Grabar","year":"2004","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0144746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T13:05:02Z","timestamp":1718283902000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0144746"}},"subtitle":[],"editor":[{"given":"Paul Richard","family":"Harrigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,29]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0144746","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,29]]}}}